Adverum Biotechnologies, Inc.
NASDAQ: ADVM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurent Fischer
- Employees
- 155
- Headquarters
- Redwood City, United States
- IPO year
- 2014
- Market cap
- $96.3M
- Website
- https://www.adverum.com
Loading ADVM…
Loading profile data…Frequently asked questions about ADVM
What does Adverum Biotechnologies, Inc. (ADVM) do?
Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a sin...
Where does ADVM trade?
Adverum Biotechnologies, Inc. (ADVM) trades on the NASDAQ Global Market.
What sector is ADVM in?
Adverum Biotechnologies, Inc. (ADVM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Adverum Biotechnologies, Inc.?
Laurent Fischer is the chief executive officer of Adverum Biotechnologies, Inc. (ADVM).
Where is Adverum Biotechnologies, Inc. headquartered?
Adverum Biotechnologies, Inc. is headquartered in United States.
Does ADVM pay a dividend?
Adverum Biotechnologies, Inc. (ADVM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADVM go public?
Adverum Biotechnologies, Inc. (ADVM) completed its initial public offering in 2014.